Priority Medical

Advanced Pharmaceutical Manufacturing Tech Hub Archives

Published on
Advanced Pharmaceutical Manufacturing Tech Hub Archives
  • Central Virginia has been designated as an Advanced Pharmaceutical Manufacturing Tech Hub, promising millions in federal funding to bolster local efforts in making pharmaceuticals more affordable and advancing the region's manufacturing capabilities.
  • Led by the Commonwealth Center for Advanced Manufacturing and the Alliance for Building Better Medicine, the initiative aims to address national needs such as medicine affordability and supply chain security, while creating good-paying jobs and enhancing economic resilience in the region.
  • The Tech Hub designation is part of a larger U.S. strategy to strengthen domestic pharmaceutical manufacturing, improve national security, and boost global competitiveness by reducing reliance on foreign supply chains, supported by investments from the CHIPS and Science Act.

Join Our Newsletter

Get the latest news, updates, and exclusive content delivered straight to your inbox.

Central Virginia has been designated as an Advanced Pharmaceutical Manufacturing (APM) Technology and Innovation Hub, a move that could bring millions of dollars in federal funding to the region. This milestone is a testament to the collaborative efforts of local organizations, universities, and the federal government, aiming to make advanced pharmaceuticals more accessible and affordable.

A Regional Effort

The designation was awarded by the U.S. Department of Commerce’s Economic Development Administration (EDA) as part of its Regional Tech Hubs Program. This program is designed to support regional consortia that demonstrate potential for rapid growth in key technology sectors, such as pharmaceutical manufacturing. Led by the Commonwealth Center for Advanced Manufacturing (CCAM), this consortium includes over 20 companies, colleges, and nonprofits in Richmond and Petersburg.

The Alliance for Building Better Medicine

At the heart of this initiative is the Alliance for Building Better Medicine, a coalition dedicated to making medicine more affordable for people. This alliance brings together diverse member organizations, including CCAM, to develop an advanced pharmaceutical manufacturing cluster. The success of this project is not just about creating jobs or boosting the local economy; it's about addressing a critical national need—ensuring that essential medicines are available to all, particularly those who struggle with high costs.

Historical Context

The journey to this designation began years ago with a series of strategic initiatives aimed at scaling up the region's pharmaceutical manufacturing capabilities. Last year, the Virginia Advanced Pharma Manufacturing (APM) Cluster received $52.9 million from the EDA's Regional Challenge program to expand the domestic supply chain for essential medicines and critical active pharmaceutical ingredients. This funding was made possible by the American Rescue Plan and the concerted efforts of Virginia Senators Mark R. Warner and Tim Kaine, who have long advocated for boosting the biotechnology sector in the Richmond region.

The Role of CCAM

The Commonwealth Center for Advanced Manufacturing (CCAM) has been instrumental in driving this initiative forward. As the lead applicant for the Alliance for Building Better Medicine, CCAM has brought together industry, academia, state and local governments, economic development organizations, and labor and workforce partners. CCAM has been solving advanced manufacturing challenges for over a decade, developing modern digital tools that address critical supply chain needs. By leveraging these capabilities, CCAM aims to address US medicine shortages and re-shore advanced pharmaceutical manufacturing.

Impact on the Region

This designation is expected to have a significant impact on Central Virginia, both economically and socially. It will increase the region’s resilience through infrastructure, supply chain, and workforce development. The project aims to create good-paying jobs and transform the region into a critical hub for the manufacturing of advanced pharmaceuticals. The hope is that these medicines will be brought to market quicker and at a lower cost, making them more affordable for people.

National Security and Global Competitiveness

Manufacturing critical medicines, including insulin, in America is crucial for national security and global competitiveness. Over-reliance on overseas manufacturing creates supply chain vulnerabilities and difficulties in pharmaceutical quality regulation and monitoring. By investing in domestic pharmaceutical manufacturing, the U.S. can strengthen its supply chains and ensure the quality of its medicines. This initiative is part of President Biden’s Investing in America agenda, which aims to empower the United States to out-innovate and out-compete the rest of the world.

The Future of Pharmaceutical Manufacturing

The Advanced Pharmaceutical Manufacturing Tech Hub in Central Virginia is part of a broader strategy to transform regional clusters into globally competitive innovation centers. The Tech Hubs Program, authorized by the CHIPS and Science Act, will invest between $50-$75 million in each of the designated hubs. This funding will support the growth, innovation, and sustainability of the U.S.-based pharmaceutical manufacturing industry. The program’s goal is to supercharge innovation across the nation by spurring cutting-edge technological investments and creating 21st-century job opportunities.

Workforce Development

One of the key aspects of this initiative is workforce development. The consortium plans to invest in training programs that will prepare the local workforce for the demands of advanced pharmaceutical manufacturing. This includes training in digital tools, supply chain management, and quality control. By developing a skilled workforce, the region can attract more industries and create a sustainable economic growth model.

Collaboration and Partnership

The success of this project is a testament to the power of collaboration and partnership. The Alliance for Building Better Medicine has brought together diverse stakeholders who share a common mission—making medicine more accessible. This synergy between industry, academia, and government is essential for driving innovation and economic growth. The region’s commitment to innovation-fueled growth and deepening its commitment to addressing affordable essential medicines is a model for other regions to follow.

Conclusion

Central Virginia’s designation as an Advanced Pharmaceutical Manufacturing Tech Hub is a significant milestone in the region’s journey towards becoming a global leader in advanced pharmaceuticals. This achievement is the result of years of strategic planning, collaborative efforts, and a shared vision to make medicine more affordable. As the region moves forward with this designation, it is poised to become a critical hub for the manufacturing of advanced pharmaceuticals, creating jobs and strengthening national security.


References

  • https://www.wtvr.com/news/local-news/alliance-for-building-better-medicine-10-26-2023
  • https://www.eda.gov/news/press-release/2023/10/23/Advanced-Pharmaceutical-Manufacturing-Tech-Hub
  • https://ccam-va.com/2023/10/25/the-power-of-partnership-the-richmond-petersburg-region-secures-designation-as-tech-hub-by-biden-harris-administration-and-u-s-department-of-commerce/
  • https://www.warner.senate.gov/public/index.cfm/2023/10/warner-and-kaine-announce-major-regional-tech-hub-wins-for-virginia
  • https://www.prnewswire.com/news-releases/the-power-of-partnership--the-richmond-petersburg-region-secures-designation-as-tech-hub-by-biden-harris-administration-and-us-department-of-commerce-301966379.html